News

Lupin gets Establishment Inspection Report from the USFDA for its Goa facilityThe US drug regulator had inspected Lupin's Goa facility, a key unit for the company, between November 10 and November 21, 2025.By Shloka Badkar  February 27, 2026, 2:40:42 PM IST (Published)1 Min ReadLupin Ltd. on Friday, February 27, said it has received an establishment inspection report (EIR) from the US Food and Drug Administration (USFDA) for its Goa facility with a satisfactory voluntary action indicated (VAI) classification.

The US drug regulator had inspected the facility from November 10, 2025 till November 21.

"The outcome reflects our continued focus on quality excellence and regulatory compliance, reinforcing our commitment to delivering safe and effective medicines to patients worldwide," Nilesh Gupta, the managing director of Lupin, said.

On another note, the pharma major on Wednesday said the GST department of Maharashtra had initiated an inspection and search at its office. It said it was cooperating with authorities and the proceedings had no impact on its financials, operations and other activities.

Earlier this week, Lupin received the USFDA's approval for its abbreviated new drug application (ANDA) for Brivaracetam oral solution in the 10mg/ml strength. It is indicated for the treatment of partial-onset seizures in patients aged one month and older.

Lupin shares were up 0.2% at ₹2,328.7 apiece around 1.55 pm. The stock has gained 22.5% in the last six months.

Also Read: Sarda Energy shares gain 8% after SC dismisses plea of unsuccessful bidders for SKS Power acquisitionContinue ReadingTagsLupinshare market today